Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Zymeworks ( (ZYME) ) is now available.
On June 26, 2025, Zymeworks Inc. amended its Pre-Funded Warrants agreement with EcoR1 Capital Fund, removing a limitation that restricted the exercise of warrants if it led to ownership exceeding 19.99% of the company’s shares. This amendment facilitated the full exercise of 5,086,521 Pre-Funded Warrants by EcoR1, resulting in the issuance of 5,086,480 shares of common stock, increasing the total outstanding shares to 74,844,505 as of June 27, 2025. The transaction was exempt from registration under the Securities Act of 1933.
The most recent analyst rating on (ZYME) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Zymeworks’ overall stock score is primarily influenced by its challenging financial performance, marked by persistent losses and cash flow issues. While technical analysis offers some stability, valuation remains weak with a negative P/E ratio. Positive earnings call highlights, including revenue growth and strategic partnerships, provide a degree of optimism, but increased expenses remain a concern.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. operates in the biotechnology industry, focusing on the development of multifunctional therapeutics. The company is known for its innovative approach in creating biotherapeutics for the treatment of cancer and other serious diseases.
Average Trading Volume: 564,863
Technical Sentiment Signal: Buy
Current Market Cap: $892.9M
For an in-depth examination of ZYME stock, go to TipRanks’ Overview page.